US20220133187A1 - Device and method for measuring blood components - Google Patents
Device and method for measuring blood components Download PDFInfo
- Publication number
- US20220133187A1 US20220133187A1 US17/542,765 US202117542765A US2022133187A1 US 20220133187 A1 US20220133187 A1 US 20220133187A1 US 202117542765 A US202117542765 A US 202117542765A US 2022133187 A1 US2022133187 A1 US 2022133187A1
- Authority
- US
- United States
- Prior art keywords
- hemoglobin
- light
- ratio
- skin
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract description 23
- 239000012503 blood component Substances 0.000 title description 3
- 241000124008 Mammalia Species 0.000 claims abstract description 20
- 108010054147 Hemoglobins Proteins 0.000 abstract description 59
- 102000001554 Hemoglobins Human genes 0.000 abstract description 59
- 210000003491 skin Anatomy 0.000 description 50
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 48
- 239000000523 sample Substances 0.000 description 36
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 34
- 108010064719 Oxyhemoglobins Proteins 0.000 description 25
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 108010002255 deoxyhemoglobin Proteins 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 230000002792 vascular Effects 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 7
- 210000000707 wrist Anatomy 0.000 description 7
- 150000003278 haem Chemical class 0.000 description 6
- 230000036564 melanin content Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 102000018146 globin Human genes 0.000 description 4
- 108060003196 globin Proteins 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 2
- 108010085682 Hemoglobin A Proteins 0.000 description 2
- 102000007513 Hemoglobin A Human genes 0.000 description 2
- 108091005880 Hemoglobin F Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010027616 Hemoglobin A2 Proteins 0.000 description 1
- 108010068308 Hemoglobin H Proteins 0.000 description 1
- 102100039894 Hemoglobin subunit delta Human genes 0.000 description 1
- 108091005903 Hemoglobin subunit delta Proteins 0.000 description 1
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 238000001055 reflectance spectroscopy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/1032—Determining colour for diagnostic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
- A61B5/7435—Displaying user selection data, e.g. icons in a graphical user interface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
- A61B5/748—Selection of a region of interest, e.g. using a graphics tablet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/443—Evaluating skin constituents, e.g. elastin, melanin, water
Definitions
- hemoglobin Hb
- O-Hb oxy-hemoglobin
- the measurement and monitoring of blood constituents is often an invasive procedure.
- the blood draw can cause discomfort to the patient and increases the risk of infection.
- the adverse effects of constant and often difficult blood draws on newborns and infants are even more pronounced.
- Frequent and constant hemoglobin measurements are clinically indicated in a wide variety of conditions such as (but not limited to) anemia, emergency and critical care including patients infected with Coronavirus Disease of 2019 (COVID-19), hemoglobinopathies such as sickle cell disease (hemoglobin-S), hematological malignancies, and peri-operative management after major surgeries such as spine surgery etc.
- these parameters are part of routine health maintenance in healthy subjects and are increasingly being used to monitor athletic performance.
- Hb and O-Hb have wide applications in healthy adults and children, athletes, patients recovering from various illnesses, as well as patients admitted in the hospital setting.
- CM cyanmethemoglobin
- CST copper sulfate technique
- AHA automated hematology analyzers
- POC point of care
- the present disclosure is directed to the measurement of hemoglobin concentration using reflectance spectroscopy.
- the advantages of this technology are a simple, portable, and easy to use hand-held device (as described below) to measure the hemoglobin (Hb) concentration in real time, and a method for continuous (or nearly continuous) non-invasive Hb monitoring. This method also offers an advantage of measuring the ratio of oxy-hemoglobin (O-Hb) concentration to the deoxy-hemoglobin (d-Hb) concentration.
- FIG. 1 is a graphical illustration of a device of the present disclosure.
- FIG. 2 is a graphical illustration of a probe of the device of the present disclosure.
- FIG. 3 is a graphical illustration of a probe of the device and a housing of the present disclosure.
- FIG. 4 is a graphical illustration of a probe near a human mammal's skin surface.
- FIG. 5 is a graphical illustration of a probe near a human mammal's skin surface.
- FIG. 6 is a graph of the reflection of light level as compared to hemoglobin level.
- FIG. 7 is a graph of the reflection of light level as compared to hemoglobin level.
- FIG. 8 is a graph of the reflection of light level as compared to hemoglobin level.
- FIG. 9 is a graph of light signal measurements over four different time points for four different areas of a human mammal's skin surface in the same mammal.
- FIG. 10 is a graph of absorption percentage over varying wavelengths for two types of hemoglobin: fetal hemoglobin (Hb-F) and adult hemoglobin (Hb-A).
- FIG. 11 is a graph of the reflection of light level as compared to hemoglobin level.
- FIG. 12 is a graph of the R value as compared to various skin colors.
- FIG. 13 is a graph of E1 to E2 ratio over time.
- the term “about” indicates that the value listed may be somewhat altered, as long as the alteration does not result in nonconformance of the process or device. For example, for some elements the term “about” can refer to a variation of ⁇ 0.1%, for other elements, the term “about” can refer to a variation of ⁇ 1% or ⁇ 10%, or any point therein.
- the term “substantially”, or “substantial”, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified, which is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result.
- a surface that is “substantially” flat would mean either completely flat, or so nearly flat that the effect would be the same as if it were completely flat.
- references in the specification to “one embodiment”, “certain embodiments”, some embodiments” or “an embodiment”, indicate that the embodiment(s) described may include a particular feature or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one skilled in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.
- the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, and derivatives thereof shall relate to the invention, as it is oriented in the drawing figures.
- the terms “overlying”, “atop”, “positioned on” or “positioned atop” means that a first element, is present on a second element, wherein intervening elements interface between the first element and the second element.
- the term “direct contact” or “attached to” means that a first element and a second element are connected without any intermediary element at the interface of the two elements.
- references herein to any numerical range expressly includes each numerical value (including fractional numbers and whole numbers) encompassed by that range.
- reference herein to a range of “at least 50” or “at least about 50” includes whole numbers of 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, etc., and fractional numbers 50.1, 50.2 50.3, 50.4, 50.5, 50.6, 50.7, 50.8, 50.9, etc.
- reference herein to a range of “less than 50” or “less than about 50” includes whole numbers 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, etc., and fractional numbers 49.9, 49.8, 49.7, 49.6, 49.5, 49.4, 49.3, 49.2, 49.1, 49.0, etc.
- the present disclosure is directed to devices and methods of measuring various blood components, such as different forms of hemoglobin, such as oxy-hemoglobin ( 0 -Hb) and deoxy-hemoglobin (d-Hb).
- hemoglobin such as oxy-hemoglobin ( 0 -Hb) and deoxy-hemoglobin (d-Hb).
- a hemoglobin molecule has two units, Heme and Globin.
- the Heme part has one iron as Fe +2 or Ferrous form and Pyrrole rings.
- Globin is tetrameric or with four amino acid chains. These chains are Alpha, Beta, Gamma and Delta globin chains. Hemoglobin therefore has a Heme and Four Globin Chains.
- Hb-A has two alpha and two beta chains. Table 1 below summarizes the three types of Hemoglobins in health.
- Hemoglobin-A Heme + ⁇ 2 ⁇ 2 Hb-A 98 to 98.5% of total hemoglobin Hemoglobin-A2 Heme + ⁇ 2 ⁇ 2 Hb-A2 1 to 1.5% of total hemoglobin Hemoglobin-F Heme + ⁇ 2 ⁇ 2 Hb-F In Newborns till around 8 months
- Oxy-hemoglobin refers to the amount of hemoglobin having oxygen bound to the heme component, while deoxy-hemoglobin refers to the amount of hemoglobin not having bound oxygen.
- Oxy-hemoglobin and total hemoglobin retain a ratio based on health. When hemoglobin is broken down, globin chains are added to the amino acid pool. Heme is split and all the Pyrrole rings open. These are later metabolized into Bilirubin. When the concentrations are high, more light is being absorbed. Hence, by measuring reflected light, as discussed further below, the concentration of oxy-hemoglobin, and deoxy-hemoglobin can be determined.
- a probe device can be utilized to measure reflected light to determine a ratio of oxy-hemoglobin to deoxy-hemoglobin.
- a probe device 100 is shown in FIG. 1 .
- Oxy-hemoglobin (O-Hb) and deoxy-hemoglobin (d-Hb) have unique spectroscopic properties as compared to each other O-Hb has an absorption peak between about 515 nm to about 535 nm, between about 520 nm to about 530 nm, or about 525 nm.
- d-Hb has an absorption peak at between about 540 nm to about 560 nm, between about 545 nm to about 555 nm, or about 550 nm.
- the device 100 can include a probe (device) 2 and a processor 4 .
- processor may refer to, is part of, or includes circuitry capable of sequentially and automatically carrying out a sequence of arithmetic or logical operations; recording, storing, and/or transferring digital data.
- processor may refer to one or more application processors, one or more baseband processors, a physical central processing unit (CPU), a single or multiple-core processor, and/or any other device capable of executing or otherwise operating computer-executable instructions, such as program code, software modules, and/or functional processes.
- the probe 2 is connected to the processor 4 through a suitable cable 3 , which is configured to transmit electrical signals.
- the probe 2 can wirelessly communicate with the processor 4 through any suitable wireless protocol, including but not limited to Wi-Fi, Bluetooth®, Near Field Communication (NFC), etc.
- the processor 4 can be within the probe 2 itself.
- the processor 4 can be included in a housing 6 .
- the housing 6 can also include an electronic storage device 10 .
- the term “electronic storage device” includes any type of integrated circuit, microcontroller and/or other storage device adapted for storing digital data including, without limitation, ROM, PROM, EEPROM, DRAM, SDRAM, DDR/2 SDRAM, EDO/FPMS, RLDRAM, SRAM, “flash” memory (e.g., NAND/NOR), 3 D memory, and PSRAM.
- the housing 6 can also include a display 8 .
- the display 8 can be any suitable display, such as a liquid crystal display (LCD), a cathode ray tube display, a light emitting diode (LED) display, or the like, which can display various information determined by the probe 2 and/or stored within the memory 10 .
- the display 8 can also be an input by receiving touch input from a user on or near a portion of the display 8 .
- the housing 6 can also include a control panel 12 , which can accept various inputs from a user. These inputs are described in more detail below.
- the housing 6 can also include an internal power supply 14 , such as a battery.
- the probe 2 and/or processor 4 can receive power from an external source.
- the probe 2 itself can include a power supply 14 .
- the probe 2 is illustrated in more detail in FIG. 2 , including a nozzle 23 of the probe 2 .
- the nozzle 23 can be any suitable, hollow, or tubular structure that can be formed to be any suitable length to allow for accurate measurement of reflected light by the probe 2 .
- each of the plurality of these light emitting diodes 22 can be the same or different, can be fixed or variable, and can be any suitable wavelength, in any suitable range, such as about 450 nm to about 580 nm. Specific examples of such wavelengths include, but are not limited to about 525 nm, about, 545 nm, about 550 nm, and about 575 nm.
- the wavelengths can differ from any of the above values by about 0.001%, about 0.01%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 7%, about 9%, about 10%, about 13%, about 15%, about 20% or more.
- the plurality of light emitting diodes 22 can be activated individually, or in any suitable sequence, to illuminate a surface, such as a skin surface (any suitable portion of the epidermis) of a mammal.
- one or more sensors 24 Upon illumination from the light emitting diodes 22 , one or more sensors 24 (two are shown in the figures for illustrative purposes), which are configured to sense an amount of light, for example a photodiode, do measure the light reflected from the surface. These one or more sensors 24 then convert that measured light to a suitable electrical signal.
- the light emitting diodes 22 can emit light at any given interval, from about 0.1 second or less, to about 0.5 seconds or more, about 1 second or more, about 5 seconds or more, about 30 seconds or more, about 1 minute or more, about 2 minutes or more, about 5 minutes or more, or about 10 minutes or more.
- the one or more sensors 24 can be configured to sense the amount of reflected light at times corresponding to whatever time period is selected for light emission.
- FIG. 3 is one embodiment of a probe 2 connected to a housing 6 , with the housing 6 including the display 8 and various inputs and controls.
- the opening at the vertical upper portion of the probe 2 is where each light is transmitted (from the plurality of light emitting diodes 22 ) and collected (by the one or more sensors 24 ) through.
- This opening can be a void, or can include a substantially transparent barrier, such as a plastic and/or glass barrier.
- the display 8 which can optionally be used as an input, can be used to display various data, such as the name of the mammal the probe 2 is to be applied to, date, time, status of the probe 2 , power indicator, total hemoglobin, oxy-hemoglobin level, deoxy-hemoglobin level, and/or a ratio of oxy-hemoglobin to deoxy-hemoglobin.
- the probe 2 can be placed into contact with any portion of a mammal's skin (S), for example a human's wrist and/or hand as shown in FIG. 4 .
- S mammal's skin
- the nozzle 23 of the probe 2 is placed near or in contact with the portion of the human's wrist and is held there by another user (or the human themselves, or by a wearable structure).
- the probe can be placed into contact with a human's forehead, as seen in FIG. 5 .
- the light emitting diodes 22 and one or more sensors 24 can be included in a wearable structure, for example, similarly to a watch.
- This wearable structure can also include the processor 4 , or the wearable structure can be configured to transmit data to the processor 4 that is external to the wearable structure.
- the light of the plurality of light emitting diodes 22 is directed towards a portion of the mammal's skin.
- a greater proportion of the light emitted from the light emitting diodes 22 is reflected back and received by the one or more sensors 24 .
- more light emitted from the light emitting diodes 22 passes through the epidermis and reflects off of both the upper vascular plexus and the lower vascular plexus, and then back again through the epidermis.
- less light is absorbed in the dermal papillae between the lower vascular plexus and the upper vascular plexus, and between the upper vascular plexus and the epidermis.
- a lesser proportion of the light emitted from the light emitting diodes 22 is reflected back and received by the one or more sensors 24 .
- less light emitted from the light emitting diodes 22 passes through the epidermis and reflects off of both the upper vascular plexus or lower vascular plexus, and then back again through the epidermis.
- more light is absorbed in the dermal papillae between the lower vascular plexus and the upper vascular plexus, and between the upper vascular plexus and the epidermis.
- FIGS. 6 and 7 The relationship between the amount of reflection of light measured as an electrical signal (current) (on the Y-axis) and amount of hemoglobin in the blood (on the X-axis) is shown in FIGS. 6 and 7 . These graphs are based on several readings from mammals, humans specifically, with different skin color. Mammals with a lighter skin have less melanin in their skin, as compared to mammals with darker skin. In FIG. 6 skin color is kept constant, so that the relationship between electrical signal and the hemoglobin concentration is linear.
- the graph illustrates the relationship between the amount of reflection of light measured as an electrical signal (current) (on the Y-axis) by the one or more sensors 24 and amount of hemoglobin in the blood (on the X-axis) of the mammal.
- the relationship is substantially linear as indicated by the straight line, which applies under the assumption that melanin concentration in the skin of the mammal (or the skin of a plurality of mammals) is substantially constant.
- the grey shaded area above the substantially straight line represents the symmetrical vertical shift in this linear relationship depending on the skin melanin concentration.
- a graph illustrates the relationship between the amount of reflection of light measured as an electrical signal (current) (on the Y-axis) by the one or more sensors 24 and amount of hemoglobin in the blood (on the X-axis) of the mammal.
- the line in FIG. 7 is substantially logarithmic due the varying melanin levels of the skin of the humans measured to arrive at the data.
- the grey shaded area above represents the vertical shift in this relationship depending on the variability in the skin melanin concentration of the mammal under measurement.
- FIG. 6 The difference between FIG. 6 and FIG. 7 demonstrates the impact melanin content of the mammal's skin can have on the accuracy of a hemoglobin reading.
- FIG. 8 is the graphical representation of data from four different individuals, with similar melanin content (as measured on the Felix Von Luschan (VLS) skin color chart), using the probe 2 on the same site in each individual (back of the wrist).
- the VLS scale provides a correlation of the color grade of a human's skin (from 1-36) to the estimated melanin content of that human's skin.
- the VLS scale can be relied upon to provide a melanin content substantially accurately for a human based on their assignment to one of 36 skin colors.
- the amount of reflection of light measured as an electrical signal (current) is plotted on the Y-axis, measured by the one or more sensors 24 , and amount of hemoglobin (measured using the conventional blood draw method) in the blood of the individual is plotted on the X-axis.
- the relationship is substantially linear as shown with the substantially straight line.
- the blood hemoglobin of the four different individuals was also measured using the standard cyanmethemoglobin laboratory technique, as shown by the four data points in FIG. 8 .
- the probe 2 could be made so that the nozzle 23 has a relatively small opening size.
- the melanin concentration of the subject's skin is finite and defined, and if the same amount of light is passed from the plurality of LEDs 22 to a smaller skin surface are of the mammal, the emitted light will encounter a relatively smaller amount of melanin. Since the concentration of melanin is typically in the microgram range, and the concentration of hemoglobin is typically in the gram range, the impact of varying melanin concentrations on optical hemoglobin determinations can be minimized.
- melanin levels can be considered, as discussed below.
- FIG. 9 is the graphical representation of the temporal and spatial data from one individual, using the probe 2 on four different sites at four different time points, each of which were about four weeks apart.
- the data points, shown as crosses, are the result of a blood draw and laboratory determination of hemoglobin (substantially constant at 14.4 g/dL).
- the amount of reflection of light measured as an electrical signal (current) by the one or more sensors 24 is plotted on the Y-axis and the corresponding time point is plotted on the X-axis.
- the readings are substantially reproducible temporally across 4 different timepoints for the same site.
- FIG. 10 is the graphical representation of data from 25 mother-infant pairs, to demonstrate similar spectroscopic properties of fetal hemoglobin (Hb-F) and adult hemoglobin (Hb-A), using the disclosed device.
- Hb-F is the predominant form of the hemoglobin in newborns and is gradually replaced by Hb-A by 8-9 months of age.
- the percentage of absorbed light is plotted on the Y-axis and the corresponding wavelength (in nanometers) is plotted on the X-axis.
- Hb-F and Hb-A have remarkably similar spectroscopic properties with the absorption peaks at 450-460 nm and 540-550 nm. Due to similar spectroscopic properties of blood hemoglobin-A and hemoglobin-F, the disclosed device can be used to measure hemoglobin concentration in adults and infants that are younger than 9 months.
- FIG. 11 is the graphical representation of data from 5 infants, with similar melanin content (as measured on the VLS scale), using the probe 2 on the same site for each infant (forehead).
- the amount of reflection of light measured as an electrical signal (current) by the one or more sensors 24 is plotted on the Y-axis and amount of hemoglobin in the blood is plotted on the X-axis.
- the five data points indicated by small circles are the laboratory results of a typical blood draw hemoglobin test.
- the relationship is substantially linear as shown by the substantially straight line, with the laboratory data being near the linear measurement results of the disclosed device.
- the “Ratio” of E1 or E2 is the ratio of light emitted by the plurality of LEDs 22 at that wavelength as compared to the amount detected by the at least one sensor 24 at that wavelength.
- the constant ‘R’ is related to the hemoglobin but also to the skin color or skin pigment melanin.
- the constant R would be a function of the amount of skin melanin and/or hemoglobin in the given subset of race/ethnicity. Therefore, this factor “R” would be different across different races/ethnicities.
- the value of R can be obtained through a melanin concentration determination. As noted above, the value of R is variable depending on the skin melanin concentration and would be constant for a specific melanin concentration. Subjects with lighter skin color (with less melanin, such as Caucasian human subjects) have higher R values, compared to the subjects with the darker skin color (with more melanin, such as African American human subjects), with R being substantially constant for subjects with the same or similar melanin concentrations.
- the mean and the standard deviation of the R values obtained in Table 2 were calculated.
- CI 95% confidence interval
- Mean+/ ⁇ 2 S.D for 95% CI is (17.89-18.81). Therefore, the R value for human subjects with the light skin tone (VLS 24-25) is expected to be around 18.35 and would fall between the intervals of 17.89 to 18.81 for at least 95% of the subjects measured.
- Table 4 is a representation of data from two human subjects. Subject X with light brown skin color (VLS grade 24) and subject Y with dark brown skin color (VLS grade 30).
- the differences between the hemoglobin values obtained using the disclosed device and conventional blood draw are remarkably small and fall well within the limits of agreement.
- the disclosed device was able to accurately estimate the blood hemoglobin value.
- the calculated values 13.69 (grams/100 ml) (for Subject X) and 14.53 (grams/100 ml) (for Subject Y) are close to the values measured by the conventional blood draw method (13.90 (grams/100 ml) and 14.8 (grams/100 ml) respectively).
- the difference between the device calculated hemoglobin value and the traditional (blood) draw measured value was about 0.2-0.3 (grams/100 ml). This difference is small and is significantly less than the currently available, approved by the Food and Drug Administration (FDA), non-invasive devices.
- FDA Food and Drug Administration
- the average R was then plotted on the Y-axis and corresponding skin color (categorical VLS scale from 1-36) on the X-axis. These results are illustrated in FIG. 12 .
- VLS 20 For subjects with light skin color (VLS 20), the mean R value was 19.5.
- VLS 24 For subjects with slightly darker skin (VLS 24), the mean R value was 18.35.
- the R value further decreases (mean value 11.73) for subjects with very dark skin (VLS 30).
- This data demonstrates a relatively consistent, substantially linear inverse relationship between the VLS scales and the R value.
- a patient enters a clinical setting.
- the operator places the probe 2 on a portion of the patient, for example the patient's wrist.
- the one or more sensors 24 detect reflected light, in this example at 525 nm and 545 nm, such that the processor 4 can determine the ratio of both of E1 and E2.
- the processor 4 makes this determination by determining the ratio of returned light detected by the one or more sensors in comparison to the emitted light from the plurality of LEDs 22 , at each wavelength.
- the processor 4 then outputs two ratios (E1) and (E2).
- the processor 4 can then add those values (E1)+(E2) (or a user can manually add those ratios) to determine a total E value.
- the VLS scale value is determined in one of two ways.
- the first way is for a user to estimate the value by a visual inspection and assignment of the patient to a score of 1-36 on the VLS scale.
- the operator can then manually select the corresponding R value for the selected score (present on a provided chart that includes all VLS scale scores and their corresponding R values).
- the operator can then manually divide the R value by E.
- the second way is for the probe 2 to include an optical sensor (one or more sensors 24 , or an additional sensor) that can receive a signal, and the processor 4 can, based on the signal, automatically assign the patient to a VLS scale value (with its corresponding R value), with those VLS scale values and R values being stored in the electronic storage device 10 .
- the processor 4 can then divide the R value by the obtained E value to determine the total hemoglobin value.
- the disclosed device can also measure the ratio of oxy-hemoglobin to deoxy-hemoglobin as well as change in the ratio, as discussed in this example.
- a patient enters a clinical setting.
- the operator places the probe 2 on a portion of the patient, for example the patient's wrists.
- the total hemoglobin value is then obtained as discussed in Example 1.
- E1 substantially corresponds to the data collected at the 525 nm wavelength, it is indicative of oxy-hemoglobin concentration
- E2 substantially corresponding to data collected at the 550 nm level (in this example, however, about 545 nm level can also be used for data collection), is indicative of deoxy-hemoglobin concentration.
- the ratio of E1 to E2 can be determined once, or sequentially to monitor the patient's condition.
- blood hemoglobin was measured with the disclosed device for a patient presenting an acute asthma attack. Asthma causes airways to become inflamed and constrict, leading to low oxygen concentration in the blood.
- the patient had a VLS skin scale of 20, with the corresponding R value of 19.5 based on a value demonstrated by FIG. 12 .
- the patient had symptoms of breathlessness and cough.
- the obtained readings are depicted immediately after presentation, at time 2 minutes (Table 5), with the disclosed device.
- Patient was then observed and treated with medications to relieve cough and breathlessness.
- patient's clinical condition deteriorated.
- Another set of readings is obtained at 21 minutes with the disclosed device.
- Patient was subsequently treated with a supplemental oxygen face mask. Patient's condition improved, and a repeat set of observations were obtained after about 20 minutes of oxygen therapy (at 40 minutes), with the disclosed device.
- the E1 divided by E2 ratio was obtained at each time point by the processor 4 .
- the ratio increased from 1.038 to 1.109 as patient's clinical condition worsened.
- patient's condition improved, and the E1/E2 ratio decreased to 0.988.
- the ratio of E1/E2 measured using the disclosed device is plotted on the Y axis, and the corresponding time point (in minutes) is plotted on the X axis.
- the patient had hypoxia (low oxygen content), with E1/E2 ratio 1.038.
- patient's condition and hypoxia worsened, with corresponding increase the ratio to 1.109.
- Patient was subsequently treated using supplemental oxygen.
- Patient's hypoxia improved, correlated with the ratio of 0.988.
- E1/E2 As seen in FIG. 13 , as the ratio of E1/E2 increases, the blood oxygen saturation (an indicator of oxyhemoglobin) decreases. Since E and H have an inverse relationship as previously described ( FIG. 6 ), the ratio E1/E2 is expected to have an inverse relationship with the relative oxy-hemoglobin (O-Hb) concentration.
- Oxy-hemoglobin is the form of hemoglobin attached to the oxygen molecules and is responsible for the oxygen delivery to the tissue.
- ratio E1/E2 provides a tool to monitor patient's clinical condition without requiring the need for the invasive arterial blood gas sampling.
- the ratio can be calculated at the bedside by a user, or the processor 4 could determine this ratio.
- Currently available non-invasive method pulse-oximetry to measure blood oxygen saturation, has limitations in dark-skinned subjects, and during low perfusion states, such as shock. The disclosed device does not have these limitations.
- ratio E1/E2 Since the relative ratios of oxy and deoxy hemoglobin are unique for each individual, the absolute value of ratio E1/E2 would vary between individuals. However, the ratio E1/E2 would be specific for the given subject and could be used through serial measurements as a non-invasive means of oxyhemoglobin monitoring. This can significantly decrease the need for the invasive blood collection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Optics & Photonics (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Human Computer Interaction (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
The present disclosure is directed to a method and device to determine a hemoglobin value of a mammal. The device includes a plurality of light emitting diodes, one or more sensors and a processor.
Description
- This application is a divisional application of co-pending application Ser. No. 17/317,171, filed on May 11, 2021, which claims the benefit of both of U.S. Provisional Patent Application Ser. No. 63/052,115 filed on Jul. 15, 2020 and U.S. Provisional Patent Application Ser. No. 63/072,504 filed on Aug. 31, 2020, the entire contents of each of which are herein incorporated by reference.
- The measurement and monitoring of blood constituents such as hemoglobin (Hb) and its species such as oxy-hemoglobin (O-Hb) is often an invasive procedure. The blood draw can cause discomfort to the patient and increases the risk of infection. The adverse effects of constant and often difficult blood draws on newborns and infants are even more pronounced. Frequent and constant hemoglobin measurements are clinically indicated in a wide variety of conditions such as (but not limited to) anemia, emergency and critical care including patients infected with Coronavirus Disease of 2019 (COVID-19), hemoglobinopathies such as sickle cell disease (hemoglobin-S), hematological malignancies, and peri-operative management after major surgeries such as spine surgery etc. In addition, these parameters are part of routine health maintenance in healthy subjects and are increasingly being used to monitor athletic performance.
- Thus, frequent measurements of Hb and O-Hb have wide applications in healthy adults and children, athletes, patients recovering from various illnesses, as well as patients admitted in the hospital setting. Although the available invasive techniques are established, they require the presence of medical personnel and laboratory equipment. Typical laboratory methods include the cyanmethemoglobin (CM) method, the copper sulfate technique (CST), the automated hematology analyzers (AHA) and the color based analytical devices. These requirements drive up the cost, as well as the amount of time for the results to be available for the clinical use. There are a few ‘point of care (POC)’ hemoglobin tests such as the HemoCue which can be done in the field or potentially at the bedside. However, it still requires obtaining a blood sample from the patient.
- There are non-invasive methods, however they suffer from variability and limitations during low perfusion states such as shock, as well as inability to measure hemoglobin values across a broad range.
- What is desired is a non-invasive system, devices, and method to measure various blood components. Embodiments of the present disclosure provide devices and methods that address the above needs.
- The present disclosure is directed to the measurement of hemoglobin concentration using reflectance spectroscopy. The advantages of this technology are a simple, portable, and easy to use hand-held device (as described below) to measure the hemoglobin (Hb) concentration in real time, and a method for continuous (or nearly continuous) non-invasive Hb monitoring. This method also offers an advantage of measuring the ratio of oxy-hemoglobin (O-Hb) concentration to the deoxy-hemoglobin (d-Hb) concentration.
- The present disclosure will be better understood by reference to the following drawings, which are provided as illustrative of certain embodiments of the subject application, and not meant to limit the scope of the present disclosure.
-
FIG. 1 is a graphical illustration of a device of the present disclosure. -
FIG. 2 is a graphical illustration of a probe of the device of the present disclosure. -
FIG. 3 is a graphical illustration of a probe of the device and a housing of the present disclosure. -
FIG. 4 is a graphical illustration of a probe near a human mammal's skin surface. -
FIG. 5 is a graphical illustration of a probe near a human mammal's skin surface. -
FIG. 6 is a graph of the reflection of light level as compared to hemoglobin level. -
FIG. 7 is a graph of the reflection of light level as compared to hemoglobin level. -
FIG. 8 is a graph of the reflection of light level as compared to hemoglobin level. -
FIG. 9 is a graph of light signal measurements over four different time points for four different areas of a human mammal's skin surface in the same mammal. -
FIG. 10 is a graph of absorption percentage over varying wavelengths for two types of hemoglobin: fetal hemoglobin (Hb-F) and adult hemoglobin (Hb-A). -
FIG. 11 is a graph of the reflection of light level as compared to hemoglobin level. -
FIG. 12 is a graph of the R value as compared to various skin colors; and -
FIG. 13 is a graph of E1 to E2 ratio over time. - In the discussion and claims herein, the term “about” indicates that the value listed may be somewhat altered, as long as the alteration does not result in nonconformance of the process or device. For example, for some elements the term “about” can refer to a variation of ±0.1%, for other elements, the term “about” can refer to a variation of ±1% or ±10%, or any point therein.
- As used herein, the term “substantially”, or “substantial”, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified, which is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result. For example, a surface that is “substantially” flat would mean either completely flat, or so nearly flat that the effect would be the same as if it were completely flat.
- As used herein terms such as “a”, “an” and “the” are not intended to refer to only a singular entity but include the general class of which a specific example may be used for illustration.
- As used herein, terms defined in the singular are intended to include those terms defined in the plural and vice versa.
- References in the specification to “one embodiment”, “certain embodiments”, some embodiments” or “an embodiment”, indicate that the embodiment(s) described may include a particular feature or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one skilled in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.
- For purposes of the description hereinafter, the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, and derivatives thereof shall relate to the invention, as it is oriented in the drawing figures. The terms “overlying”, “atop”, “positioned on” or “positioned atop” means that a first element, is present on a second element, wherein intervening elements interface between the first element and the second element. The term “direct contact” or “attached to” means that a first element and a second element are connected without any intermediary element at the interface of the two elements.
- Reference herein to any numerical range expressly includes each numerical value (including fractional numbers and whole numbers) encompassed by that range. To illustrate, reference herein to a range of “at least 50” or “at least about 50” includes whole numbers of 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, etc., and fractional numbers 50.1, 50.2 50.3, 50.4, 50.5, 50.6, 50.7, 50.8, 50.9, etc. In a further illustration, reference herein to a range of “less than 50” or “less than about 50” includes
whole numbers - The present disclosure is directed to devices and methods of measuring various blood components, such as different forms of hemoglobin, such as oxy-hemoglobin (0-Hb) and deoxy-hemoglobin (d-Hb).
- A hemoglobin molecule has two units, Heme and Globin. The Heme part has one iron as Fe+2 or Ferrous form and Pyrrole rings. Globin is tetrameric or with four amino acid chains. These chains are Alpha, Beta, Gamma and Delta globin chains. Hemoglobin therefore has a Heme and Four Globin Chains. For example, Hb-A has two alpha and two beta chains. Table 1 below summarizes the three types of Hemoglobins in health.
-
TABLE 1 Hemoglobin-A Heme + α2β2 Hb-A 98 to 98.5% of total hemoglobin Hemoglobin-A2 Heme + α2δ2 Hb-A2 1 to 1.5% of total hemoglobin Hemoglobin-F Heme + α2γ2 Hb-F In Newborns till around 8 months - Oxy-hemoglobin refers to the amount of hemoglobin having oxygen bound to the heme component, while deoxy-hemoglobin refers to the amount of hemoglobin not having bound oxygen. Oxy-hemoglobin and total hemoglobin retain a ratio based on health. When hemoglobin is broken down, globin chains are added to the amino acid pool. Heme is split and all the Pyrrole rings open. These are later metabolized into Bilirubin. When the concentrations are high, more light is being absorbed. Hence, by measuring reflected light, as discussed further below, the concentration of oxy-hemoglobin, and deoxy-hemoglobin can be determined.
- Based on the above a probe device can be utilized to measure reflected light to determine a ratio of oxy-hemoglobin to deoxy-hemoglobin. For example, a
probe device 100 is shown inFIG. 1 . Oxy-hemoglobin (O-Hb) and deoxy-hemoglobin (d-Hb) have unique spectroscopic properties as compared to each other O-Hb has an absorption peak between about 515 nm to about 535 nm, between about 520 nm to about 530 nm, or about 525 nm. d-Hb has an absorption peak at between about 540 nm to about 560 nm, between about 545 nm to about 555 nm, or about 550 nm. - The
device 100 can include a probe (device) 2 and aprocessor 4. As used herein, the term “processor” may refer to, is part of, or includes circuitry capable of sequentially and automatically carrying out a sequence of arithmetic or logical operations; recording, storing, and/or transferring digital data. The term “processor” may refer to one or more application processors, one or more baseband processors, a physical central processing unit (CPU), a single or multiple-core processor, and/or any other device capable of executing or otherwise operating computer-executable instructions, such as program code, software modules, and/or functional processes. - In this embodiment the
probe 2 is connected to theprocessor 4 through asuitable cable 3, which is configured to transmit electrical signals. However, in other embodiments, theprobe 2 can wirelessly communicate with theprocessor 4 through any suitable wireless protocol, including but not limited to Wi-Fi, Bluetooth®, Near Field Communication (NFC), etc. In yet other embodiments, theprocessor 4 can be within theprobe 2 itself. - The
processor 4 can be included in ahousing 6. Thehousing 6 can also include anelectronic storage device 10. As used herein, the term “electronic storage device” includes any type of integrated circuit, microcontroller and/or other storage device adapted for storing digital data including, without limitation, ROM, PROM, EEPROM, DRAM, SDRAM, DDR/2 SDRAM, EDO/FPMS, RLDRAM, SRAM, “flash” memory (e.g., NAND/NOR), 3D memory, and PSRAM. - The
housing 6 can also include adisplay 8. Thedisplay 8 can be any suitable display, such as a liquid crystal display (LCD), a cathode ray tube display, a light emitting diode (LED) display, or the like, which can display various information determined by theprobe 2 and/or stored within thememory 10. Optionally, thedisplay 8 can also be an input by receiving touch input from a user on or near a portion of thedisplay 8. Alternatively, or in addition to, thedisplay 8 being an input, thehousing 6 can also include acontrol panel 12, which can accept various inputs from a user. These inputs are described in more detail below. - Optionally, in this embodiment, the
housing 6 can also include aninternal power supply 14, such as a battery. However, in other embodiments, theprobe 2 and/orprocessor 4 can receive power from an external source. In yet other embodiments, theprobe 2 itself can include apower supply 14. - The
probe 2 is illustrated in more detail inFIG. 2 , including anozzle 23 of theprobe 2. Thenozzle 23 can be any suitable, hollow, or tubular structure that can be formed to be any suitable length to allow for accurate measurement of reflected light by theprobe 2. - In
FIG. 2 , within theprobe housing 20 are a plurality oflight emitting diodes 22. The wavelengths of each of the plurality of theselight emitting diodes 22 can be the same or different, can be fixed or variable, and can be any suitable wavelength, in any suitable range, such as about 450 nm to about 580 nm. Specific examples of such wavelengths include, but are not limited to about 525 nm, about, 545 nm, about 550 nm, and about 575 nm. However, in other embodiments, the wavelengths can differ from any of the above values by about 0.001%, about 0.01%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 7%, about 9%, about 10%, about 13%, about 15%, about 20% or more. - The plurality of
light emitting diodes 22 can be activated individually, or in any suitable sequence, to illuminate a surface, such as a skin surface (any suitable portion of the epidermis) of a mammal. - Upon illumination from the
light emitting diodes 22, one or more sensors 24 (two are shown in the figures for illustrative purposes), which are configured to sense an amount of light, for example a photodiode, do measure the light reflected from the surface. These one ormore sensors 24 then convert that measured light to a suitable electrical signal. In the present disclosure, thelight emitting diodes 22 can emit light at any given interval, from about 0.1 second or less, to about 0.5 seconds or more, about 1 second or more, about 5 seconds or more, about 30 seconds or more, about 1 minute or more, about 2 minutes or more, about 5 minutes or more, or about 10 minutes or more. Accordingly, the one ormore sensors 24 can be configured to sense the amount of reflected light at times corresponding to whatever time period is selected for light emission. -
FIG. 3 is one embodiment of aprobe 2 connected to ahousing 6, with thehousing 6 including thedisplay 8 and various inputs and controls. The opening at the vertical upper portion of theprobe 2 is where each light is transmitted (from the plurality of light emitting diodes 22) and collected (by the one or more sensors 24) through. This opening can be a void, or can include a substantially transparent barrier, such as a plastic and/or glass barrier. - The
display 8, which can optionally be used as an input, can be used to display various data, such as the name of the mammal theprobe 2 is to be applied to, date, time, status of theprobe 2, power indicator, total hemoglobin, oxy-hemoglobin level, deoxy-hemoglobin level, and/or a ratio of oxy-hemoglobin to deoxy-hemoglobin. - The
probe 2 can be placed into contact with any portion of a mammal's skin (S), for example a human's wrist and/or hand as shown inFIG. 4 . As can be seen inFIG. 4 , thenozzle 23 of theprobe 2 is placed near or in contact with the portion of the human's wrist and is held there by another user (or the human themselves, or by a wearable structure). - In another embodiment, the probe can be placed into contact with a human's forehead, as seen in
FIG. 5 . - Alternatively, to the probe of
FIGS. 4 and 5 , thelight emitting diodes 22 and one ormore sensors 24 can be included in a wearable structure, for example, similarly to a watch. This wearable structure can also include theprocessor 4, or the wearable structure can be configured to transmit data to theprocessor 4 that is external to the wearable structure. - Regardless of
probe 2 structure, during operation of the disclosed device in determining oxy-hemoglobin level, deoxy-hemoglobin level, and/or a ratio of oxy-hemoglobin to deoxy-hemoglobin, the light of the plurality oflight emitting diodes 22 is directed towards a portion of the mammal's skin. - If that mammal has a relatively low hemoglobin level, a greater proportion of the light emitted from the
light emitting diodes 22 is reflected back and received by the one ormore sensors 24. For example, more light emitted from thelight emitting diodes 22 passes through the epidermis and reflects off of both the upper vascular plexus and the lower vascular plexus, and then back again through the epidermis. Thus, in this example, less light is absorbed in the dermal papillae between the lower vascular plexus and the upper vascular plexus, and between the upper vascular plexus and the epidermis. - In contrast, if that mammal has a relatively high hemoglobin level, a lesser proportion of the light emitted from the
light emitting diodes 22 is reflected back and received by the one ormore sensors 24. For example, less light emitted from thelight emitting diodes 22 passes through the epidermis and reflects off of both the upper vascular plexus or lower vascular plexus, and then back again through the epidermis. Thus, in this example, more light is absorbed in the dermal papillae between the lower vascular plexus and the upper vascular plexus, and between the upper vascular plexus and the epidermis. - The relationship between the reflection of light and hemoglobin levels is discussed below in reference to
FIGS. 6 and 7 . - The relationship between the amount of reflection of light measured as an electrical signal (current) (on the Y-axis) and amount of hemoglobin in the blood (on the X-axis) is shown in
FIGS. 6 and 7 . These graphs are based on several readings from mammals, humans specifically, with different skin color. Mammals with a lighter skin have less melanin in their skin, as compared to mammals with darker skin. InFIG. 6 skin color is kept constant, so that the relationship between electrical signal and the hemoglobin concentration is linear. - Specifically in
FIG. 6 , the graph illustrates the relationship between the amount of reflection of light measured as an electrical signal (current) (on the Y-axis) by the one ormore sensors 24 and amount of hemoglobin in the blood (on the X-axis) of the mammal. The relationship is substantially linear as indicated by the straight line, which applies under the assumption that melanin concentration in the skin of the mammal (or the skin of a plurality of mammals) is substantially constant. The grey shaded area above the substantially straight line represents the symmetrical vertical shift in this linear relationship depending on the skin melanin concentration. - In partial contrast to
FIG. 6 , as seen inFIG. 7 a graph illustrates the relationship between the amount of reflection of light measured as an electrical signal (current) (on the Y-axis) by the one ormore sensors 24 and amount of hemoglobin in the blood (on the X-axis) of the mammal. The line inFIG. 7 is substantially logarithmic due the varying melanin levels of the skin of the humans measured to arrive at the data. The grey shaded area above represents the vertical shift in this relationship depending on the variability in the skin melanin concentration of the mammal under measurement. - The difference between
FIG. 6 andFIG. 7 demonstrates the impact melanin content of the mammal's skin can have on the accuracy of a hemoglobin reading. - As a further demonstration of the effect melanin has on hemoglobin determinations, data is presented and discussed with reference to
FIGS. 7-10 . -
FIG. 8 is the graphical representation of data from four different individuals, with similar melanin content (as measured on the Felix Von Luschan (VLS) skin color chart), using theprobe 2 on the same site in each individual (back of the wrist). The VLS scale provides a correlation of the color grade of a human's skin (from 1-36) to the estimated melanin content of that human's skin. Thus, the VLS scale can be relied upon to provide a melanin content substantially accurately for a human based on their assignment to one of 36 skin colors. - Referring again to
FIG. 8 , the amount of reflection of light measured as an electrical signal (current) is plotted on the Y-axis, measured by the one ormore sensors 24, and amount of hemoglobin (measured using the conventional blood draw method) in the blood of the individual is plotted on the X-axis. The relationship is substantially linear as shown with the substantially straight line. As a comparison, the blood hemoglobin of the four different individuals was also measured using the standard cyanmethemoglobin laboratory technique, as shown by the four data points inFIG. 8 . As can be seen, there is a substantially accurate correlation between measured light values translated to hemoglobin content as compared to blood tested hemoglobin levels. - As one way to correct for the influence varying melanin levels has on optical hemoglobin determinations, the
probe 2 could be made so that thenozzle 23 has a relatively small opening size. Under this embodiment, the melanin concentration of the subject's skin is finite and defined, and if the same amount of light is passed from the plurality ofLEDs 22 to a smaller skin surface are of the mammal, the emitted light will encounter a relatively smaller amount of melanin. Since the concentration of melanin is typically in the microgram range, and the concentration of hemoglobin is typically in the gram range, the impact of varying melanin concentrations on optical hemoglobin determinations can be minimized. - As another way to correct for the influence varying melanin levels has on optical hemoglobin determinations, melanin levels can be considered, as discussed below.
- In another example,
FIG. 9 is the graphical representation of the temporal and spatial data from one individual, using theprobe 2 on four different sites at four different time points, each of which were about four weeks apart. The data points, shown as crosses, are the result of a blood draw and laboratory determination of hemoglobin (substantially constant at 14.4 g/dL). - The amount of reflection of light measured as an electrical signal (current) by the one or
more sensors 24 is plotted on the Y-axis and the corresponding time point is plotted on the X-axis. As seen from the graph, the readings are substantially reproducible temporally across 4 different timepoints for the same site. However, there is significant difference across readings obtained from different sites. For example, the amount of reflected light from the wrist is higher and it progressively decreases from wrist-thumb-palm-forehead. Therefore, eachprobe 2 can be designed for a specific reading location, or theprobe 2 andprocessor 4 can be adjusted to account for the different reading location. -
FIG. 10 is the graphical representation of data from 25 mother-infant pairs, to demonstrate similar spectroscopic properties of fetal hemoglobin (Hb-F) and adult hemoglobin (Hb-A), using the disclosed device. Hb-F is the predominant form of the hemoglobin in newborns and is gradually replaced by Hb-A by 8-9 months of age. The percentage of absorbed light is plotted on the Y-axis and the corresponding wavelength (in nanometers) is plotted on the X-axis. Hb-F and Hb-A have remarkably similar spectroscopic properties with the absorption peaks at 450-460 nm and 540-550 nm. Due to similar spectroscopic properties of blood hemoglobin-A and hemoglobin-F, the disclosed device can be used to measure hemoglobin concentration in adults and infants that are younger than 9 months. - As a further demonstration of this,
FIG. 11 is the graphical representation of data from 5 infants, with similar melanin content (as measured on the VLS scale), using theprobe 2 on the same site for each infant (forehead). The amount of reflection of light measured as an electrical signal (current) by the one ormore sensors 24 is plotted on the Y-axis and amount of hemoglobin in the blood is plotted on the X-axis. The five data points indicated by small circles are the laboratory results of a typical blood draw hemoglobin test. The relationship is substantially linear as shown by the substantially straight line, with the laboratory data being near the linear measurement results of the disclosed device. - Further, Table 2 below includes data from four human subjects, with light brown skin color (VLS scale 24-25). Corresponding R values are calculated using the formula, R=E*H. This E was obtained using the disclosed device, and the blood hemoglobin concentration (H) was obtained using the conventional blood draw method. In Table 2, as well as the rest of the disclosure, the “Ratio” of E1 or E2 is the ratio of light emitted by the plurality of
LEDs 22 at that wavelength as compared to the amount detected by the at least onesensor 24 at that wavelength. -
TABLE 2 Hb (H) measured by blood draw Subject Ratio E1 Ratio E2 Total Ratio (grams/ R value = no. (525 nm) (545 nm) E = E1 + E2 100 ml) E* H 1 0.692 0.671 1.363 13.71 18.69 2 0.736 0.749 1.485 12.29 18.25 3 0.633 0.616 1.249 14.56 18.19 4 0.650 0.626 1.276 14.32 18.27 E1 = Ratio of reflected light using the 525 nm LED of the disclosed device E2 = Ratio of reflected light using the 545 nm LED of the disclosed device - In Table 2 above and throughout the disclosure, the constant ‘R’ is related to the hemoglobin but also to the skin color or skin pigment melanin. The constant R would be a function of the amount of skin melanin and/or hemoglobin in the given subset of race/ethnicity. Therefore, this factor “R” would be different across different races/ethnicities.
- R can be further depicted as, R=kM Where ‘M’ represents variable concentration of Melanin in the skin and ‘k’ is the constant factor related to the hemoglobin.
- Due to two variables E (either 1 or 2) and M, the nature of the mathematical relationship between E and H could be substantially linear or substantially logarithmic, and the relationship could be depicted using a substantially logarithmic scale (
FIG. 7 noted above) as: R=log (E*H) - The value of R (since R=kM) is dependent on the amount of melanin “M” in the skin. If the value of M is kept substantially constant, the value of R would be substantially constant. In other words, the value of R will be substantially constant for the subjects with the same skin melanin concentration (M). In such case, the relationship would tend to be substantially linear, and can be expressed (
FIG. 6 ) as: R=E*H - Because the disclosed device measures E at various wavelengths, the amount of hemoglobin H (in grams/100 ml) in the blood can be calculated by the
processor 4, with the formula: H (in grams/100 ml)=R/E - The value of R can be obtained through a melanin concentration determination. As noted above, the value of R is variable depending on the skin melanin concentration and would be constant for a specific melanin concentration. Subjects with lighter skin color (with less melanin, such as Caucasian human subjects) have higher R values, compared to the subjects with the darker skin color (with more melanin, such as African American human subjects), with R being substantially constant for subjects with the same or similar melanin concentrations.
- The mean and the standard deviation of the R values obtained in Table 2 were calculated. The mean calculated R value, with the standard deviation (S.D), in this case is (mean=18.35, S.D=0.23). Using a 95% confidence interval (CI) for the data of Table 2 case would be: Mean+/−2 S.D for 95% CI is (17.89-18.81). Therefore, the R value for human subjects with the light skin tone (VLS 24-25) is expected to be around 18.35 and would fall between the intervals of 17.89 to 18.81 for at least 95% of the subjects measured.
- Similarly, to Table 2 above, Table 3 below is a representation of data from three human subjects, with dark brown skin color (VLS scale 30-31). Corresponding R values were calculated using the formula, R=E*H. Although only one time point is listed in Table 3 for each of the subjects, in other examples, multiple measurements can be undertaken for each subject. These multiple measurements can span the time ranges noted above, such as continuous or near continuous measurement, up to a measurement every several minutes or more.
-
TABLE 3 Hb (H) measured by blood draw. Subject Ratio 1 Ratio 2Total Ratio (grams/ R value = no (525 nm) (545 nm) E = E1 + E2 100 ml) E* H 1 0.360 0.368 0.728 15.71 11.43 2 0.396 0.395 0.791 14.60 11.55 3 0.382 0.367 0.749 16.30 12.21 E1 = Ratio of reflected light using the 525 nm LED of the disclosed device E2 = Ratio of reflected light using the 545 nm LED of the disclosed device - Similarly, to the procedure in Table 2, discussed above, for the data of Table 3, the calculated mean and S.D was (mean=11.73, S.D=0.42). Thus, using a 95% confidence interval (CI) for Table 3, Mean+/−2 S.D for 95% CI is (10.89-12.57). Therefore, the R value for subjects with the dark skin tone (VLS scale 30-31) is expected to be around 11.73 and would fall between the intervals of 10.89 to 12.57 for at least 95% of the subjects measured.
- Table 4 is a representation of data from two human subjects. Subject X with light brown skin color (VLS grade 24) and subject Y with dark brown skin color (VLS grade 30).
-
TABLE 4 R value for Total hemoglobin each skin color (H, (grams/100 ml) Hemoglobin obtained from calculated by measured Ratio Ratio Total previous the device using using Difference Skin E1 E2 Ratio experiments H = R/E with blood draw. (grams/100 ml) Subject color (525 nm) (550 nm) E = E1 + E2 with (95% C.I. ) (95% C.I.) (grams/100 ml) %) X Light 0.668 0.672 1.340 18.35 (17.89-18.81) 13.69 (13.35-14.0) 13.90 (−0.21, 1.5) Y Dark 0.411 0.396 0.807 11.73 (10.89-12.57) 14.53 (13.49-15.58) 14.80 (−0.27, 1.82) E1 = Ratio of reflected light using the 525 nm LED of the disclosed device. E2 = Ratio of reflected light using the 545 nm LED of the disclosed device. 95% C.I. = 95% confidence interval obtained by Mean ± 2 (Standard deviation). - In Table 4, for each subject, values of E were obtained using the disclosed device (column 4). Next, depending upon the skin color, corresponding mean R values (with 95% C.I.) for each skin color were chosen as shown in column 5 (based on Tables 2 and 3 above). Hemoglobin values were calculated using the formula, H=R/E, and are shown in
column 6 along with the limits of agreement. These values were compared to those obtained by the conventional blood draw method (column 7). - As shown in
column 8, the differences between the hemoglobin values obtained using the disclosed device and conventional blood draw are remarkably small and fall well within the limits of agreement. Specifically, for both subject X and subject Y, the disclosed device was able to accurately estimate the blood hemoglobin value. The calculated values 13.69 (grams/100 ml) (for Subject X) and 14.53 (grams/100 ml) (for Subject Y) are close to the values measured by the conventional blood draw method (13.90 (grams/100 ml) and 14.8 (grams/100 ml) respectively). In both examples, the difference between the device calculated hemoglobin value and the traditional (blood) draw measured value was about 0.2-0.3 (grams/100 ml). This difference is small and is significantly less than the currently available, approved by the Food and Drug Administration (FDA), non-invasive devices. - As a further example, multiple readings were obtained from a number of subjects with different skin colors using the disclosed device on the back of each of their wrists. The R value and mean were calculated for each individual relied on for data in Tables 2 and 3.
- The average R was then plotted on the Y-axis and corresponding skin color (categorical VLS scale from 1-36) on the X-axis. These results are illustrated in
FIG. 12 . For subjects with light skin color (VLS 20), the mean R value was 19.5. For subjects with slightly darker skin (VLS 24), the mean R value was 18.35. The R value further decreases (mean value 11.73) for subjects with very dark skin (VLS 30). This data demonstrates a relatively consistent, substantially linear inverse relationship between the VLS scales and the R value. These findings support that the R value is significantly lower (around 5-10) in subjects with higher VLS scales as compared (around 35-40) to subjects with lower VLS scales. - In this example, a patient enters a clinical setting. The operator then places the
probe 2 on a portion of the patient, for example the patient's wrist. - The one or
more sensors 24 detect reflected light, in this example at 525 nm and 545 nm, such that theprocessor 4 can determine the ratio of both of E1 and E2. Theprocessor 4 makes this determination by determining the ratio of returned light detected by the one or more sensors in comparison to the emitted light from the plurality ofLEDs 22, at each wavelength. - The
processor 4 then outputs two ratios (E1) and (E2). Theprocessor 4 can then add those values (E1)+(E2) (or a user can manually add those ratios) to determine a total E value. Next, the VLS scale value is determined in one of two ways. - The first way is for a user to estimate the value by a visual inspection and assignment of the patient to a score of 1-36 on the VLS scale. Under this first option, the operator can then manually select the corresponding R value for the selected score (present on a provided chart that includes all VLS scale scores and their corresponding R values). The operator can then manually divide the R value by E.
- The second way is for the
probe 2 to include an optical sensor (one ormore sensors 24, or an additional sensor) that can receive a signal, and theprocessor 4 can, based on the signal, automatically assign the patient to a VLS scale value (with its corresponding R value), with those VLS scale values and R values being stored in theelectronic storage device 10. Theprocessor 4 can then divide the R value by the obtained E value to determine the total hemoglobin value. - In addition to the total hemoglobin as described above in Example 1, the disclosed device can also measure the ratio of oxy-hemoglobin to deoxy-hemoglobin as well as change in the ratio, as discussed in this example.
- In this example, a patient enters a clinical setting. The operator then places the
probe 2 on a portion of the patient, for example the patient's wrists. The total hemoglobin value is then obtained as discussed in Example 1. - Further, since E1 substantially corresponds to the data collected at the 525 nm wavelength, it is indicative of oxy-hemoglobin concentration, while E2, substantially corresponding to data collected at the 550 nm level (in this example, however, about 545 nm level can also be used for data collection), is indicative of deoxy-hemoglobin concentration. The ratio of E1 to E2 can be determined once, or sequentially to monitor the patient's condition.
- In this example, blood hemoglobin was measured with the disclosed device for a patient presenting an acute asthma attack. Asthma causes airways to become inflamed and constrict, leading to low oxygen concentration in the blood. The patient had a VLS skin scale of 20, with the corresponding R value of 19.5 based on a value demonstrated by
FIG. 12 . - At first, the patient had symptoms of breathlessness and cough. The obtained readings are depicted immediately after presentation, at
time 2 minutes (Table 5), with the disclosed device. Patient was then observed and treated with medications to relieve cough and breathlessness. However, patient's clinical condition deteriorated. Another set of readings is obtained at 21 minutes with the disclosed device. Patient was subsequently treated with a supplemental oxygen face mask. Patient's condition improved, and a repeat set of observations were obtained after about 20 minutes of oxygen therapy (at 40 minutes), with the disclosed device. -
TABLE 5 Calculated Hb Measured Hb Oxygen saturation Total R value using the device. using the using arterial Time Ratio E1 Ratio E2 Ratio ratio for skin H = R/E blood draw method. blood gas (mins) (525 nm) (550 nm) E1/E2 (E1 + E2) VLS 20 (grants/100 ml) (grams/100 ml) (normal 97-100%) 2 min (room air) 0.631 0.608 1.038 1.239 19.50 15.74 15.30 90% 21 min (room air) 0.652 0.588 1.109 1.240 19.50 15.73 15.40 86% 40 min 0.615 0.622 0.988 1.237 19.50 15.76 15.30 96% (Oxygen face mask) E1 = Ratio of reflected light using the 525 nm LED of the disclosed device E2 = Ratio of reflected light using the 545 nm LED of the disclosed device - The E1 divided by E2 ratio was obtained at each time point by the
processor 4. As seen from Table 5, the ratio increased from 1.038 to 1.109 as patient's clinical condition worsened. After treatment with the supplemental oxygen, patient's condition improved, and the E1/E2 ratio decreased to 0.988. These results are shown in theFIG. 13 . - Specifically, in
FIG. 13 , the ratio of E1/E2 measured using the disclosed device, is plotted on the Y axis, and the corresponding time point (in minutes) is plotted on the X axis. At presentation, the patient had hypoxia (low oxygen content), with E1/E2 ratio 1.038. After 20 minutes, patient's condition and hypoxia worsened, with corresponding increase the ratio to 1.109. Patient was subsequently treated using supplemental oxygen. Patient's hypoxia improved, correlated with the ratio of 0.988. - As seen in
FIG. 13 , as the ratio of E1/E2 increases, the blood oxygen saturation (an indicator of oxyhemoglobin) decreases. Since E and H have an inverse relationship as previously described (FIG. 6 ), the ratio E1/E2 is expected to have an inverse relationship with the relative oxy-hemoglobin (O-Hb) concentration. Oxy-hemoglobin is the form of hemoglobin attached to the oxygen molecules and is responsible for the oxygen delivery to the tissue. - Therefore, ratio E1/E2 provides a tool to monitor patient's clinical condition without requiring the need for the invasive arterial blood gas sampling. The ratio can be calculated at the bedside by a user, or the
processor 4 could determine this ratio. Currently available non-invasive method (pulse-oximetry) to measure blood oxygen saturation, has limitations in dark-skinned subjects, and during low perfusion states, such as shock. The disclosed device does not have these limitations. - Since the relative ratios of oxy and deoxy hemoglobin are unique for each individual, the absolute value of ratio E1/E2 would vary between individuals. However, the ratio E1/E2 would be specific for the given subject and could be used through serial measurements as a non-invasive means of oxyhemoglobin monitoring. This can significantly decrease the need for the invasive blood collection.
- The described embodiments and examples of the present disclosure are intended to be illustrative rather than restrictive and are not intended to represent every embodiment or example of the present disclosure. While the fundamental novel features of the disclosure as applied to various specific embodiments thereof have been shown, described, and pointed out, it will also be understood that various omissions, substitutions and changes in the form and details of the devices illustrated and in their operation, may be made by those skilled in the art without departing from the spirit of the disclosure. For example, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the disclosure. Moreover, it should be recognized that structures and/or elements and/or method steps shown and/or described in connection with any disclosed form or embodiment of the disclosure may be incorporated in any other disclosed or described or suggested form or embodiment as a general matter of design choice. Further, various modifications and variations can be made without departing from the spirit or scope of the disclosure as set forth in the following claims both literally and in equivalents recognized in law.
Claims (5)
1. A device comprising:
a plurality of light emitting diodes configured to emit light at two or more wavelengths towards a surface of a mammal's skin surface.
one or more sensors configured to detect a reflected light, wherein the reflected light is the emitted light that passes through at least a portion of the mammal's skin and is at least partially reflected towards the one or more sensors; and
a processor configured to:
receive the detected, reflected light.
determine a first ratio of reflected light, wherein the first ratio is a percentage of light emitted in a range of about 515 nm to about 535 nm as compared to the light reflected in the range of about 515 nm to about 535 nm.
determine a second ratio of reflected light, wherein the second ratio is a percentage of light emitted in a range of about 535 nm to about 555 nm as compared to the light reflected in the range of about 535 nm to about 555 nm: and
determine an E1/E2 ratio by dividing the first ratio by the second ratio.
2. The device of claim 1 , wherein
the first ratio is the percentage of light emitted in the range of about 520 nm to about 530 nm as compared to the light reflected in the range of about 520 nm to about 530 nm: and
the second ratio is the percentage of light emitted in the range of about 540 nm to about 550 nm as compared to the light reflected in the range of about 540 nm to about 550 nm.
3. The device of claim 1 , wherein
the first ratio is the percentage of light emitted in the range of about 525 as compared to the light reflected in the range of about 525; and
the second ratio is the percentage of light emitted in the range of about 545 nm as compared to the light reflected in the range of about 545.
4. The device of claim 1 , wherein the processor is configured to output the one or more levels to a display that is configured to display text and/or images of the one or more levels.
5. The device of claim 4 , wherein the display is configured to receive a touch input.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/542,765 US20220133187A1 (en) | 2020-07-15 | 2021-12-06 | Device and method for measuring blood components |
US17/581,415 US20220142531A1 (en) | 2020-07-15 | 2022-01-21 | Device and method for measuring blood constituents |
US17/749,269 US20220273205A1 (en) | 2020-07-15 | 2022-05-20 | Device and method for measuring blood and skin components |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063052115P | 2020-07-15 | 2020-07-15 | |
US202063072504P | 2020-08-31 | 2020-08-31 | |
US17/317,171 US11191460B1 (en) | 2020-07-15 | 2021-05-11 | Device and method for measuring blood components |
US17/542,765 US20220133187A1 (en) | 2020-07-15 | 2021-12-06 | Device and method for measuring blood components |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/317,171 Division US11191460B1 (en) | 2020-07-15 | 2021-05-11 | Device and method for measuring blood components |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/581,415 Continuation-In-Part US20220142531A1 (en) | 2020-07-15 | 2022-01-21 | Device and method for measuring blood constituents |
US17/749,269 Continuation-In-Part US20220273205A1 (en) | 2020-07-15 | 2022-05-20 | Device and method for measuring blood and skin components |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220133187A1 true US20220133187A1 (en) | 2022-05-05 |
Family
ID=78818525
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/317,171 Active US11191460B1 (en) | 2020-07-15 | 2021-05-11 | Device and method for measuring blood components |
US17/542,765 Abandoned US20220133187A1 (en) | 2020-07-15 | 2021-12-06 | Device and method for measuring blood components |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/317,171 Active US11191460B1 (en) | 2020-07-15 | 2021-05-11 | Device and method for measuring blood components |
Country Status (4)
Country | Link |
---|---|
US (2) | US11191460B1 (en) |
EP (1) | EP3968858A4 (en) |
JP (1) | JP2023533622A (en) |
WO (1) | WO2022015778A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11191460B1 (en) * | 2020-07-15 | 2021-12-07 | Shani Biotechnologies LLC | Device and method for measuring blood components |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830137A (en) * | 1996-11-18 | 1998-11-03 | University Of South Florida | Green light pulse oximeter |
US20200015735A1 (en) * | 2018-07-16 | 2020-01-16 | Bruin Biometrics, Llc | Perfusion and oxygenation measurement |
US11191460B1 (en) * | 2020-07-15 | 2021-12-07 | Shani Biotechnologies LLC | Device and method for measuring blood components |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3638640A (en) | 1967-11-01 | 1972-02-01 | Robert F Shaw | Oximeter and method for in vivo determination of oxygen saturation in blood using three or more different wavelengths |
JPS6039982B2 (en) | 1977-07-26 | 1985-09-09 | オリンパス光学工業株式会社 | liquid sample analyzer |
US4257862A (en) | 1978-07-24 | 1981-03-24 | Eastman Kodak Company | Chemical analyzer |
US4272245A (en) | 1978-12-04 | 1981-06-09 | Transidyne General Corporation | Method and apparatus for electro-chemical measurement |
US4397725A (en) | 1980-12-15 | 1983-08-09 | Transidyne General Corp. | Apparatus for measuring electrochemical activity |
US4714341A (en) | 1984-02-23 | 1987-12-22 | Minolta Camera Kabushiki Kaisha | Multi-wavelength oximeter having a means for disregarding a poor signal |
US4723554A (en) | 1984-04-27 | 1988-02-09 | Massachusetts Institute Of Technology | Skin pallor and blush monitor |
US5041187A (en) | 1988-04-29 | 1991-08-20 | Thor Technology Corporation | Oximeter sensor assembly with integral cable and method of forming the same |
US5111817A (en) | 1988-12-29 | 1992-05-12 | Medical Physics, Inc. | Noninvasive system and method for enhanced arterial oxygen saturation determination and arterial blood pressure monitoring |
EP0442011A1 (en) | 1990-02-15 | 1991-08-21 | Hewlett-Packard GmbH | Sensor, apparatus and method for non-invasive measurement of oxygen saturation |
US5242832A (en) | 1990-03-01 | 1993-09-07 | Toa Medical Electronics Co., Ltd. | Reagent for measurement of leukocytes and hemoglobin in blood |
GB9011887D0 (en) | 1990-05-26 | 1990-07-18 | Le Fit Ltd | Pulse responsive device |
US6266546B1 (en) | 1990-10-06 | 2001-07-24 | In-Line Diagnostics Corporation | System for noninvasive hematocrit monitoring |
US5277181A (en) | 1991-12-12 | 1994-01-11 | Vivascan Corporation | Noninvasive measurement of hematocrit and hemoglobin content by differential optical analysis |
US5377674A (en) | 1992-05-08 | 1995-01-03 | Kuestner; J. Todd | Method for non-invasive and in-vitro hemoglobin concentration measurement |
US5452717A (en) | 1993-07-14 | 1995-09-26 | Masimo Corporation | Finger-cot probe |
EP0683641A4 (en) * | 1993-08-24 | 1998-07-15 | Mark R Robinson | A robust accurate non-invasive analyte monitor. |
JP3464697B2 (en) | 1993-12-21 | 2003-11-10 | 興和株式会社 | Oxygen saturation meter |
US5692503A (en) | 1995-03-10 | 1997-12-02 | Kuenstner; J. Todd | Method for noninvasive (in-vivo) total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination |
DE19612425C2 (en) | 1995-03-31 | 2000-08-31 | Nihon Kohden Corp | Apparatus for measuring hemoglobin concentration |
SE504193C2 (en) | 1995-04-21 | 1996-12-02 | Hemocue Ab | Capillary microcuvette |
FI962448A (en) | 1996-06-12 | 1997-12-13 | Instrumentarium Oy | Method, apparatus and sensor for the determination of fractional oxygen saturation |
US5879294A (en) | 1996-06-28 | 1999-03-09 | Hutchinson Technology Inc. | Tissue chromophore measurement system |
US5800349A (en) | 1996-10-15 | 1998-09-01 | Nonin Medical, Inc. | Offset pulse oximeter sensor |
US5763280A (en) | 1997-01-21 | 1998-06-09 | Coulter International Corp. | Cyanide-free lytic reagent composition and method for hemoglobin and cell analysis |
US5842979A (en) | 1997-02-14 | 1998-12-01 | Ohmeda Inc. | Method and apparatus for improved photoplethysmographic monitoring of oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin |
IL124965A (en) | 1998-06-17 | 2002-08-14 | Orsense Ltd | Non-invasive method of optical measurements for determining concentration of a substance in blood |
US6064898A (en) | 1998-09-21 | 2000-05-16 | Essential Medical Devices | Non-invasive blood component analyzer |
US6305804B1 (en) | 1999-03-25 | 2001-10-23 | Fovioptics, Inc. | Non-invasive measurement of blood component using retinal imaging |
US6622095B2 (en) | 1999-11-30 | 2003-09-16 | Nihon Kohden Corporation | Apparatus for determining concentrations of hemoglobins |
US6594513B1 (en) | 2000-01-12 | 2003-07-15 | Paul D. Jobsis | Method and apparatus for determining oxygen saturation of blood in body organs |
FR2806609B1 (en) | 2000-03-24 | 2002-10-11 | Medick S A | METHOD AND DEVICE FOR NON-INVASIVE MEASUREMENT OF TISSUE AND IN PARTICULAR OF THE BILIRUBIN LEVEL OF THE SKIN |
US6554788B1 (en) | 2000-06-02 | 2003-04-29 | Cobe Cardiovascular, Inc. | Hematocrit sampling system |
US6606509B2 (en) | 2001-03-16 | 2003-08-12 | Nellcor Puritan Bennett Incorporated | Method and apparatus for improving the accuracy of noninvasive hematocrit measurements |
KR100612827B1 (en) | 2001-04-19 | 2006-08-14 | 삼성전자주식회사 | Method and apparatus for noninvasively measuring hemoglobin concentration and oxygen saturation |
US6819949B2 (en) | 2001-04-30 | 2004-11-16 | University Of Alabama In Huntsville | Method and apparatus for measuring blood oxygen saturation in a retinal vessel by separately detecting single pass optical signals |
US6802812B1 (en) | 2001-07-27 | 2004-10-12 | Nostix Llc | Noninvasive optical sensor for measuring near infrared light absorbing analytes |
US20050010091A1 (en) | 2003-06-10 | 2005-01-13 | Woods Joe W. | Non-invasive measurement of blood glucose using retinal imaging |
SE0104443D0 (en) | 2001-12-28 | 2001-12-28 | Hemocue Ab | Analysis method and cuvette for that |
US8175610B2 (en) | 2002-06-07 | 2012-05-08 | Nokia Corporation | Apparatus, and an associated method, for facilitating airlink resource management in a radio communication system |
US6763256B2 (en) | 2002-08-16 | 2004-07-13 | Optical Sensors, Inc. | Pulse oximeter |
US7838296B2 (en) | 2002-08-28 | 2010-11-23 | Separation Technology, Inc. | Methods and apparatus for ultrasonic determination of red blood cell indices |
JP2004113353A (en) | 2002-09-25 | 2004-04-15 | Citizen Watch Co Ltd | Blood analyzer |
US7379167B2 (en) | 2003-02-11 | 2008-05-27 | International Technidyne Corporation | Hemoglobin test strip and analysis system |
US6968221B2 (en) | 2003-03-14 | 2005-11-22 | Futrex, Inc. | Low-cost method and apparatus for non-invasively measuring blood glucose levels |
US7430445B2 (en) | 2003-04-24 | 2008-09-30 | The Board Of Regents Of The University Of Texas System | Noninvasive blood analysis by optical probing of the veins under the tongue |
AU2004294569A1 (en) | 2003-11-26 | 2005-06-16 | Separation Technology, Inc. | Method and apparatus for ultrasonic determination of hematocrit and hemoglobin concentrations |
US20050267346A1 (en) | 2004-01-30 | 2005-12-01 | 3Wave Optics, Llc | Non-invasive blood component measurement system |
US7277741B2 (en) | 2004-03-09 | 2007-10-02 | Nellcor Puritan Bennett Incorporated | Pulse oximetry motion artifact rejection using near infrared absorption by water |
US7551950B2 (en) | 2004-06-29 | 2009-06-23 | O2 Medtech, Inc,. | Optical apparatus and method of use for non-invasive tomographic scan of biological tissues |
US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
US7288759B2 (en) | 2004-09-09 | 2007-10-30 | Beth Israel Deaconess Medical Center, Inc. | Tissue-like phantoms |
US7608042B2 (en) | 2004-09-29 | 2009-10-27 | Intellidx, Inc. | Blood monitoring system |
US20070129618A1 (en) | 2005-06-20 | 2007-06-07 | Daniel Goldberger | Blood parameter testing system |
US7254432B2 (en) | 2005-08-17 | 2007-08-07 | Orsense Ltd. | Method and device for non-invasive measurements of blood parameters |
EP1924195A2 (en) | 2005-09-13 | 2008-05-28 | Edwards Lifesciences Corporation | Continuous spectroscopic measurement of total hemoglobin |
CA2630094A1 (en) | 2005-11-15 | 2007-05-24 | Luminous Medical, Inc. | Blood analyte determinations |
SE530244C2 (en) | 2006-05-05 | 2008-04-08 | Hemocue Ab | Method and system for quantitative hemoglobin determination |
SE531041C2 (en) | 2006-07-17 | 2008-11-25 | Hemocue Ab | Platelet count |
US8417305B2 (en) | 2007-05-02 | 2013-04-09 | St. Vincents Hospital (Melbourne) Limited | Non-invasive measurement of blood oxygen saturation |
BRPI0802336A2 (en) | 2008-04-17 | 2009-12-29 | Gomes Paulo Alberto Paes | process, handheld equipment and device for in vitro photometric determination of hemoglobin concentration in a one-step diluted blood sample |
US8130369B2 (en) | 2008-11-05 | 2012-03-06 | Fresenius Medical Care Holdings, Inc. | Measuring hematocrit and estimating hemoglobin values with a non-invasive, optical blood monitoring system |
US8348844B2 (en) | 2008-12-02 | 2013-01-08 | Kislaya Kunjan | Automated blood sampler and analyzer |
EP2249161B1 (en) | 2009-05-05 | 2020-05-13 | InfanDx AG | Method of diagnosing asphyxia |
US8571619B2 (en) | 2009-05-20 | 2013-10-29 | Masimo Corporation | Hemoglobin display and patient treatment |
US20110082355A1 (en) | 2009-07-30 | 2011-04-07 | Oxitone Medical Ltd. | Photoplethysmography device and method |
JP2013533774A (en) | 2010-07-09 | 2013-08-29 | セント ヴィンセンツ ホスピタル(メルボルン)リミテッド | Non-invasive measurement of blood oxygen saturation |
US8730460B2 (en) | 2011-04-08 | 2014-05-20 | William Marsh Rice University | Paper based spectrophotometric detection of blood hemoglobin concentration |
US8603309B2 (en) | 2011-09-12 | 2013-12-10 | Nova Biomedical Corporation | Disposable sensor for electrochemical detection of hemoglobin |
US9161364B2 (en) | 2011-12-21 | 2015-10-13 | Qualcomm Incorporated | Methods and apparatus for assignment dependent downlink channel processing for wireless networks |
IN2012DE02074A (en) | 2012-07-03 | 2015-08-14 | Srivastava Ambar | |
US11653874B2 (en) * | 2013-02-01 | 2023-05-23 | Acceleritas Corporation | Method and system for characterizing tissue in three dimensions using multimode optical measurements |
US20140276013A1 (en) * | 2013-03-13 | 2014-09-18 | Cephalogics, LLC | Optical tomography sensor and related apparatus and methods |
WO2014192781A1 (en) * | 2013-05-30 | 2014-12-04 | Hoya株式会社 | Method and device for generating image showing concentration distribution of biological substances in biological tissue |
US10444232B2 (en) | 2014-08-13 | 2019-10-15 | The Trustees Of Columbia University In The City Of New York | Diagnostic devices, systems, and methods |
US10231657B2 (en) | 2014-09-04 | 2019-03-19 | Masimo Corporation | Total hemoglobin screening sensor |
USD739945S1 (en) | 2014-10-21 | 2015-09-29 | Roche Diabetes Care, Inc. | Blood glucose meter |
CN104931441A (en) | 2015-06-15 | 2015-09-23 | 马国鹭 | Method and device for quickly detecting hemoglobin |
US9642578B2 (en) | 2015-07-19 | 2017-05-09 | Sanmina Corporation | System and method for health monitoring using a non-invasive, multi-band biosensor |
US10426396B2 (en) * | 2016-02-10 | 2019-10-01 | Hill-Rom Services, Inc. | Pressure ulcer detection systems and methods |
KR102427034B1 (en) * | 2016-04-22 | 2022-07-29 | 바이압틱스 인코포레이티드 | Determination of absolute and relative tissue oxygen saturation |
-
2021
- 2021-05-11 US US17/317,171 patent/US11191460B1/en active Active
- 2021-07-14 WO PCT/US2021/041507 patent/WO2022015778A1/en unknown
- 2021-07-14 JP JP2021577956A patent/JP2023533622A/en active Pending
- 2021-07-14 EP EP21820080.6A patent/EP3968858A4/en active Pending
- 2021-12-06 US US17/542,765 patent/US20220133187A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830137A (en) * | 1996-11-18 | 1998-11-03 | University Of South Florida | Green light pulse oximeter |
US20200015735A1 (en) * | 2018-07-16 | 2020-01-16 | Bruin Biometrics, Llc | Perfusion and oxygenation measurement |
US11191460B1 (en) * | 2020-07-15 | 2021-12-07 | Shani Biotechnologies LLC | Device and method for measuring blood components |
Also Published As
Publication number | Publication date |
---|---|
US11191460B1 (en) | 2021-12-07 |
JP2023533622A (en) | 2023-08-04 |
EP3968858A4 (en) | 2023-06-21 |
EP3968858A1 (en) | 2022-03-23 |
WO2022015778A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hanning et al. | Fortnightly review: pulse oximetry: a practical review | |
Jensen et al. | Meta-analysis of arterial oxygen saturation monitoring by pulse oximetry in adults | |
US10238346B2 (en) | System and method for a biosensor integrated in a vehicle | |
Luks et al. | Pulse oximetry at high altitude | |
US20030144582A1 (en) | Portable non-invasive glucose monitor | |
Nesseler et al. | Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors | |
Shiao et al. | Validation of oxygen saturation monitoring in neonates | |
Willems et al. | Transcutaneous bilirubinometry with the Bilicheck® in very premature newborns | |
JP2004290544A (en) | Blood analyzer | |
Smith et al. | Perioperative comparison of the agreement between a portable fingertip pulse oximeter v. a conventional bedside pulse oximeter in adult patients (COMFORT trial) | |
Rochmanto et al. | Non-invasive hemoglobin measurement for anemia diagnosis | |
Kyriacou | Introduction to photoplethysmography | |
US20220133187A1 (en) | Device and method for measuring blood components | |
Nirupa et al. | Non-invasive measurement of hemoglobin content in blood | |
Cabanas et al. | Improving pulse oximetry accuracy in dark-skinned patients: technical aspects and current regulations | |
Mackenzie | Comparison of a pulse oximeter with an ear oximeter and an in-vitro oximeter | |
da Costa et al. | Comparison of the accuracy of a pocket versus standard pulse oximeter | |
Hossain et al. | Estimation of molar absorption coefficients of HbA1c in near UV-Vis-SW NIR light spectrum | |
Welch | Pulse oximeters | |
US20220142531A1 (en) | Device and method for measuring blood constituents | |
Choi et al. | Performance of the MP570T pulse oximeter in volunteers participating in the controlled desaturation study: a comparison of seven probes | |
US20220273205A1 (en) | Device and method for measuring blood and skin components | |
Ogburn-Russell et al. | Oxygen saturation levels in the well elderly: altitude makes a difference | |
Gokhale et al. | Developing a novel device based on a new technology for non-invasive measurement of blood biomarkers irrespective of skin color | |
Samuel et al. | Embedded Based Low Cost Pulse Oximeter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |